var title_f39_36_40512="Botulinum toxin injection sites for peau d orange chin";
var content_f39_36_40512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Example of botulinum toxin injection sites for peau d'orange chin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Injections are placed into the mentalis muscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40512=[""].join("\n");
var outline_f39_36_40512=null;
var title_f39_36_40513="Calculator: Pressure ulcer risk stratification (Braden score)";
var content_f39_36_40513=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"PressureUlcerRisk_form\" name=\"PressureUlcerRisk_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Pressure ulcer risk stratification (Braden score)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Sensory perception",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Completely limited (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very limited (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Slightly limited (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No limitation (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Moisture",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Constantly moist (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moist (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Occasionally moist (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Rarely moist (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Activity",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Bedfast (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Chairfast (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Slight limitation (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No limitation (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Mobility",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Immobile (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Quite limited (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Slight limitation (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Normal mobility (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Nutrition",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Very poor (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Inadequate (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Adequate (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Excellent (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Friction/shear",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Problematic (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Potentially problematic (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"PressureUlcerRisk_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          Risk Score",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           17 to 23 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Minimal risk",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           15 to 16 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Low risk",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           13 to 14 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Moderate risk",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0 to 12 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           High risk",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Braden BJ, Bergstrom N. Risk assessment and risk-based programs of prevention in various settings.",
"        <i>",
"         Ostomy/Wound Management",
"        </i>",
"        . 1996 Vol. 42 No. 10A:6S-12S.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Wellard S, Lo K. Comparing Norton, Braden and Waterlow risk assessment scales for pressure ulcers in spinal cord injuries.",
"        <i>",
"         Contemp Nurse",
"        </i>",
"        . 2000 Jun;9(2):155-60.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"PressureUlcerRisk_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40513=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function PressureUlcerRisk_fx() {",
"with(document.PressureUlcerRisk_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 1;",
"}",
"if (cc1[1].checked){",
"Score = Score + 2;",
"}",
"if (cc1[2].checked){",
"Score = Score + 3;",
"}",
"if (cc1[3].checked){",
"Score = Score + 4;",
"}",
"if (cc2[0].checked){",
"Score = Score + 1;",
"}",
"if (cc2[1].checked){",
"Score = Score + 2;",
"}",
"if (cc2[2].checked){",
"Score = Score + 3;",
"}",
"if (cc2[3].checked){",
"Score = Score + 4;",
"}",
"if (cc3[0].checked){",
"Score = Score + 1;",
"}",
"if (cc3[1].checked){",
"Score = Score + 2;",
"}",
"if (cc3[2].checked){",
"Score = Score + 3;",
"}",
"if (cc3[3].checked){",
"Score = Score + 4;",
"}",
"if (cc4[0].checked){",
"Score = Score + 1;",
"}",
"if (cc4[1].checked){",
"Score = Score + 2;",
"}",
"if (cc4[2].checked){",
"Score = Score + 3;",
"}",
"if (cc4[3].checked){",
"Score = Score + 4;",
"}",
"if (cc5[0].checked){",
"Score = Score + 1;",
"}",
"if (cc5[1].checked){",
"Score = Score + 2;",
"}",
"if (cc5[2].checked){",
"Score = Score + 3;",
"}",
"if (cc5[3].checked){",
"Score = Score + 4;",
"}",
"if (cc6[0].checked){",
"Score = Score + 1;",
"}",
"if (cc6[1].checked){",
"Score = Score + 2;",
"}",
"if (cc6[2].checked){",
"Score = Score + 3;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 17) && (Score <= 23)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 15) && (Score <= 16)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 13) && (Score <= 14)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 0) && (Score <= 12)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f39_36_40513=null;
var title_f39_36_40514="Pain Pathogenesis LPHS";
var content_f39_36_40514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Proposed pathogenesis of pain in patients with primary LPHS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 687px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the proposed mechanism is initiated by glomerular hematuria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: Spetie DN, Nadasdy T, Nadasdy G, Agarwal G, Mauer M, Agarwal AK, Khabiri H, Nagaraja, HN, Nahman Jr NS, Hartman JA, Hebert LA: Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis 47(3):419-427, 2006. Copyright &copy; 2006 National Kidney Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40514=[""].join("\n");
var outline_f39_36_40514=null;
var title_f39_36_40515="Hepatic vein cannulation rotated";
var content_f39_36_40515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transjugular liver biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopic image of the right upper quadrant of the abdomen showing a catheter with a metallic cannula (arrow) rotated away from the center of the vein pointing toward the liver parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40515=[""].join("\n");
var outline_f39_36_40515=null;
var title_f39_36_40516="Pentazocine and naloxone: Patient drug information";
var content_f39_36_40516=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentazocine and naloxone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32757?source=see_link\">",
"     see \"Pentazocine and naloxone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use tablets by mouth only. Do not misuse this drug and do not give as a shot. Does not mix with street drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentazocine, naloxone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have GI (gastrointestinal) disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12283 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-2522EA1FE6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40516=[""].join("\n");
var outline_f39_36_40516=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022672\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022674\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022673\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022678\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022679\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022681\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022676\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022677\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022682\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022683\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32757?source=related_link\">",
"      Pentazocine and naloxone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_36_40517="Ethacrynic acid: Patient drug information";
var content_f39_36_40517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethacrynic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/10/7334?source=see_link\">",
"     see \"Ethacrynic acid: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/11/29877?source=see_link\">",
"     see \"Ethacrynic acid: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Edecrin&reg;;",
"     </li>",
"     <li>",
"      Sodium Edecrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Edecrin&reg;;",
"     </li>",
"     <li>",
"      Sodium Edecrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is a strong water pill. Sometimes too much water and major elements (potassium) in the blood may be lost. Your doctor will follow you closely to change the dose to match your body's needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702071",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethacrynic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug caused very loose stools (diarrhea) before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need extra potassium. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hearing loss. This can be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Measure liquid doses carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature. Throw away any part not used after 7 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12021 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40517=[""].join("\n");
var outline_f39_36_40517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167963\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167964\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021942\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021944\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021943\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021948\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021949\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021951\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021946\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021947\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021952\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021953\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/10/7334?source=related_link\">",
"      Ethacrynic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/11/29877?source=related_link\">",
"      Ethacrynic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_36_40518="Confluent and reticulated papillomatosis - close view";
var content_f39_36_40518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Confluent and reticulated papillomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Close view of hyperpigmented, reticulated thin plaques in confluent reticulated papillomatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40518=[""].join("\n");
var outline_f39_36_40518=null;
var title_f39_36_40519="Advanced case 11 with answer";
var content_f39_36_40519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Atrial septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram in a patient with a large atrial septal defect (3:1 shunt). There is right ventricular conduction delay with right axis deviation due to right ventricular hypertrophy. (qR complexes are sometimes seen in leads V1 and V2 with right-sided chamber enlargement). The tall P waves in V2 and V3 are due to right atrial enlargement. In comparison, mitral stenosis is associated with right ventricular hypertrophy plus left (not right) atrial enlargement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40519=[""].join("\n");
var outline_f39_36_40519=null;
var title_f39_36_40520="Second-line therapy for patients with previously treated advanced non-small cell lung cancer";
var content_f39_36_40520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/36/40520/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/36/40520/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/36/40520/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/36/40520/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/36/40520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/36/40520/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/36/40520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial systemic therapy (chemotherapy or targeted agents) may delay disease progression and prolong survival in patients with advanced non-small cell lung cancer (NSCLC). However, almost all patients eventually develop progressive disease.",
"   </p>",
"   <p>",
"    The development of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    was conducted before the routine use of EGFR mutation testing. EGFR TKIs were initially approved as second-line agents for patients who had progressed while receiving treatment with chemotherapy. With the current understanding of the epidermal growth factor pathway, EGFR TKIs now typically are employed as the initial therapy for advanced disease in patients whose tumors contain characteristic mutations, while cytotoxic chemotherapy remains the preferred treatment for patients without such mutations.",
"   </p>",
"   <p>",
"    For patients with disseminated disease who require additional therapy after an initial systemic treatment, second-line treatment with either chemotherapy or epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may provide symptom palliation and increase survival in selected patients. The choice of second-line therapy depends upon the initial treatment administered as well as the mutation status of the patient.",
"   </p>",
"   <p>",
"    When symptoms are due to progressive disease within the chest or from metastatic involvement of a single or limited number of sites, locoregional therapy may provide useful palliation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second-line therapy will be discussed here. An overview of the management of advanced NSCLC is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    are approved for second-line chemotherapy after progression on an earlier chemotherapy regimen, based upon results of phase III trials. The use of pemetrexed is generally restricted to patients with nonsquamous histology. The choice of agent is also influenced by the specific chemotherapy regimen used in the patient&rsquo;s initial treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefits of second-line chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    were initially demonstrated in a trial in which 104 patients with previously treated stage IIIB or IV NSCLC were randomly assigned to docetaxel monotherapy (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) or best supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients assigned to docetaxel had significantly longer overall survival (median 7.5 versus 4.6 months, one-year survival rate 37 versus 11 percent). Side effects such as febrile neutropenia were less common in patients treated with the 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    regimen. Furthermore, patients treated with docetaxel had improved pain control and significantly less deterioration in quality of life compared to those managed only with best supportive care, in whom pain control worsened over the course of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/2\">",
"     2",
"    </a>",
"    ]. Other randomized trials comparing docetaxel with older agents also support the activity of docetaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    on a weekly schedule, rather than every three weeks, has been advocated to minimize toxicity while not losing efficacy. Multiple randomized clinical trials and a meta-analysis have confirmed the utility of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. As an example, in one trial, 220 patients were randomly assigned to docetaxel every three weeks (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or weekly (33.3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    for six of every eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/4\">",
"     4",
"    </a>",
"    ]. Median survival and one-year survival rates were similar (29 versus 25 weeks and 21 versus 31 percent, respectively). Weekly administration of docetaxel caused significantly less grade 3 or 4 hematologic toxicity (6 versus 25 percent with the three week schedule) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/4\">",
"     4",
"    </a>",
"    ]. However, other toxicities were more common, including particularly excessive tearing (epiphora) due to stenosis of the tear ducts (dacryostenosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. This can be severe and may necessitate discontinuation of docetaxel therapy in up to 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     Docetaxel",
"    </a>",
"    was compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    in a large randomized trial, which demonstrated a similar level of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Although docetaxel treatment was associated with increased toxicity, it remains the preferred agent for patients with squamous cell histology. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pemetrexed'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    is as active and has less toxicity than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    for second-line therapy in patients with advanced NSCLC. Pemetrexed is generally restricted to patients with nonsquamous histology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Effect of histology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These agents were compared in a phase III trial in which 571 patients with recurrent NSCLC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    each given every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Treatment was continued until there was disease progression or unacceptable toxicity. Pemetrexed was combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (350 to 1000 mcg daily) and vitamin B12 (1000 mcg every nine weeks) to decrease the incidence of hematologic toxicity.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    (4 mg twice daily for three days) was given to minimize cutaneous toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H30#H30\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Exanthematous (morbilliform) rashes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The objective response rates were similar (9 percent for both agents), as was overall survival (median 8 months in each group). However,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      was associated with significantly less grade 3 or 4 neutropenia (5 versus 40 percent), febrile neutropenia (2 versus 13 percent), use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      support (3 versus 19 percent), and hair loss (6 versus 38 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a secondary analysis of this trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      was more active than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      in patients with nonsquamous tumors (overall survival median 9.3 versus 8.0 months, hazard ratio [HR] for death 0.78, 95% CI 0.61-1.00) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/15\">",
"       15",
"      </a>",
"      ]. In contrast, pemetrexed was less effective than docetaxel in patients with squamous carcinomas (overall survival 6.2 versus 7.4 months, HR 1.56, 95% CI 1.08-2.26). This impact of histology on response to treatment with pemetrexed is consistent with the preferential activity of pemetrexed for patients with nonsquamous NSCLC in the first-line setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H12#H12\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Effect of histology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other chemotherapy agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive data are available on the activity of multiple agents when given as monotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ). However, these agents have not been adequately evaluated in randomized trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Active single agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505317\">",
"    <span class=\"h2\">",
"     Elderly and poor performance status patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of chemotherapy agent for second-line therapy is similar in elderly and poor performance status patients, although treatment should be individualized and needs to consider the patient&rsquo;s overall condition.",
"   </p>",
"   <p>",
"    In a subset analysis of a trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], both agents were well tolerated in patients 70 years of age or more who had received prior chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/16\">",
"     16",
"    </a>",
"    ]. Survival was similar in the 86 elderly patients compared to those less than age 70 years (9.5 versus 7.8 months with pemetrexed and 7.7 versus 8.0 months with docetaxel).",
"   </p>",
"   <p>",
"    A comprehensive geriatric assessment may be useful in determining whether a patient is a candidate for second-line therapy and to formulate an appropriate, individualized treatment plan. Special considerations for the use of chemotherapy in the elderly population are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy does not appear to improve overall survival compared to single agent chemotherapy in previously treated patients. A meta-analysis analyzed data from 847 individual patients who were enrolled on one of six trials in which patients were randomly assigned to either single agent chemotherapy or a chemotherapy doublet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/17\">",
"     17",
"    </a>",
"    ]. Trials that incorporated a targeted agent were excluded.",
"   </p>",
"   <p>",
"    Although there was a significant increase in progression-free survival (14 versus 12 weeks, HR for progression 0.79, 95% CI 0.68-0.91), this was accompanied by an increase in both hematologic and nonhematologic grade 3 or 4 toxicity. Overall survival with combination chemotherapy was not significantly prolonged compared to single agent therapy (median 37 versus 35 weeks, one-year survival 34 versus 32 percent, hazard ratio [HR] 0.92, 95% CI 0.79-1.08).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Retreatment after initial response",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients who have progressed after one chemotherapy regimen are treated with a non-cross-resistant regimen. However, patients who have responded to an initial chemotherapy regimen and then remain stable for at least six months after treatment discontinuation may benefit from retreatment with the same regimen used in the first-line setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Relapse after adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who receive adjuvant chemotherapy after definitive therapy eventually relapse. Defining the appropriate treatment strategy, including the possible readministration of drugs used in the adjuvant regimen and the use of non-cross-resistant regimens, has become an important issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/19\">",
"     19",
"    </a>",
"    ]. Although there are no randomized trials in this setting, these patients are typically managed as chemotherapy-naive first line patients if they relapse more than 12 months after the completion of adjuvant therapy; thus these patients usually receive combination regimens. Patients who relapse less than 12 months after adjuvant therapy are candidates for single agent chemotherapy. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872312\">",
"    <span class=\"h1\">",
"     TARGETED AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1137259613\">",
"    <span class=\"h2\">",
"     EGFR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    were originally developed as second-line therapy for patients with advanced NSCLC who had disease progression after treatment with cytotoxic chemotherapy. The trials with these agents as second-line therapy were largely conducted before the key role of EGFR mutations had been identified.",
"   </p>",
"   <p>",
"    A large phase III trial found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    improved overall survival compared with best supportive care alone in patients who had previously received one or two chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    was compared with best supportive care in patients who had progressed on prior chemotherapy and were not candidates for additional chemotherapy in the ISEL trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/21\">",
"     21",
"    </a>",
"    ]. That trial failed to demonstrate a statistically significant improvement in overall survival compared with best supportive care, and this negative result led to withdrawal of regulatory approval in the United States. &nbsp;",
"   </p>",
"   <p>",
"    Randomized trials comparing EGFR TKIs with single agent chemotherapy have not established the superiority of either approach, and both EGFR TKIs and single agent chemotherapy are appropriate options in this setting. (See",
"    <a class=\"local\" href=\"#H200193586\">",
"     'Chemotherapy versus EGFR inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505032\">",
"    <span class=\"h2\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is a monoclonal antibody that binds to the EGFR, thus providing an alternative approach to blocking the epidermal growth factor pathway.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    does not have a role as second-line therapy in patients with NSCLC. In the phase III SELECT trial, 605 patients previously treated patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    with or without cetuximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/22\">",
"     22",
"    </a>",
"    ]. Preliminary results were presented at the 2012 ASCO meeting. There was no improvement in progression-free survival, the primary endpoint of the trial, with the addition of cetuximab compared with pemetrexed alone (2.9 versus 2.8 months, HR 1.03, 95% CI 0.87-1.21).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     VEGF pathway inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a monoclonal antibody that interferes with angiogenesis by binding vascular endothelial growth factor (VEGF). Combinations of bevacizumab with platinum-based chemotherapy have increased progression-free and overall survival when used for the initial systemic management of carefully selected patients with advanced nonsquamous NSCLC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    does not have an established role in previously treated patients. In a phase III trial, 636 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    plus bevacizumab or erlotinib alone in patients who had progressed after standard first-line chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/23\">",
"     23",
"    </a>",
"    ]. There was an increase in progression-free survival and objective response rate with the combination of bevacizumab plus erlotinib (median 3.4 versus 1.7 months and 13 versus 6 percent, respectively). However, there was no significant difference in overall survival with the addition of bevacizumab compared with erlotinib alone (median 9.3 versus 9.2 months, HR for death 0.97).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     Aflibercept",
"    </a>",
"    is a recombinant human fusion protein that binds to VEGF, thus providing an alternative pathway to block the VEGF pathway. In a phase III trial the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus aflibercept was no more effective than docetaxel plus placebo in prolonging overall survival as second line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200200473\">",
"    <span class=\"h2\">",
"     Crizotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical studies assessing the activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    have been limited to patients whose tumor contained this characteristic molecular abnormality. There are no data to support the use of crizotinib as second-line therapy in patients whose tumor does not contain the ALK fusion oncogene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link&amp;anchor=H518894165#H518894165\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200193586\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY VERSUS EGFR INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple clinical trials have been conducted that compare chemotherapy with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    after an initial course of therapy with platinum-based chemotherapy. These trials have not observed a difference in overall survival, regardless of EGFR mutation status. However, progression-free survival appears to be prolonged with an EGFR inhibitor in patients whose tumor contains an EGFR mutation; in those without an EGFR mutation, PFS appears to be longer with chemotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TITAN trial, 424 patients who had initially been treated with a platinum-based doublet were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or chemotherapy (either single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , at the treating investigator&rsquo;s discretion) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/25\">",
"       25",
"      </a>",
"      ]. At a median follow-up of over two years, there was no significant difference in overall survival (median 5.3 versus 5.5 months, HR for death 0.96, for erlotinib versus chemotherapy). EGFR mutations were present in 11 of the 424 (2.6 percent) patients enrolled in the trial.",
"     </li>",
"     <li>",
"      In the INTEREST trial, 1444 patients who had previously received one or more platinum-based regimens were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/26\">",
"       26",
"      </a>",
"      ]. There was no difference in overall survival between the two treatment arms (median 7.6 versus 8.0 months, HR 1.02). EGFR mutations were present in 44 of the 297 patients who were able to be analyzed (15 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with an EGFR mutation, progression-free survival was significantly prolonged with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (median 7.0 versus 4.1 months, HR 0.16); however, this did not result in an increase in overall survival (median 14.2 versus 16.6 months, HR 0.83, 95% CI 0.41-1.67).",
"     </li>",
"     <li>",
"      In patients without an EGFR mutation, there was no difference in overall survival (median 6.4 versus 6.0 months, HR 1.02, for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ), although there was a statistically nonsignificant trend toward a shorter progression-free survival with gefitinib (median 1.7 versus 2.6 months, HR 1.24).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TAILOR trial, 222 patients were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      as second-line therapy after platinum-based combination chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/27\">",
"       27",
"      </a>",
"      ]. All patients in this trial had tumor assessed for EGFR mutations and all were wild-type. In preliminary results presented at the 2012 ASCO meeting, progression-free survival was significantly better with docetaxel chemotherapy compared with erlotinib (median 3.4 versus 2.4 months, HR 0.69, 95% CI 0.52-0.93). Overall survival results are pending.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505604\">",
"    <span class=\"h1\">",
"     EGFR MUTATED TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose tumors contain mutations in the EGFR are generally managed with an EGFR tyrosine kinase inhibitor as their initial therapy for advanced disease. When these patients progress, the subsequent use of cytotoxic chemotherapy is patterned after that in patients with chemotherapy na&iuml;ve disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Results from observational studies suggest that continuation of an EGFR tyrosine kinase inhibitor in combination with cytotoxic chemotherapy may have a benefit in some patients with progressive disease, but these observations require additional confirmation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link&amp;anchor=H1191492196#H1191492196\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are initially treated with chemotherapy and subsequently found to have an EGFR mutation generally should complete their initial chemotherapy. Targeted therapy should be integrated into subsequent treatment planning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link&amp;anchor=H798956916#H798956916\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\", section on 'Chemotherapy versus targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272525172\">",
"    <span class=\"h1\">",
"     ALK FUSION ONCOGENE TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the ALK fusion oncogene confers sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    , an inhibitor of the anaplastic lymphoma kinase (ALK) tyrosine kinase. Crizotinib is generally used as initial therapy for patients with advanced NSCLC whose tumors contain the ALK fusion oncogene. When these patients relapse, their subsequent management generally includes combination chemotherapy that is patterned after those who are chemotherapy na&iuml;ve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are initially treated with chemotherapy and whose tumor is subsequently found to have an ALK fusion oncogene generally should complete their initial chemotherapy. Targeted therapy should be integrated into subsequent treatment planning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link&amp;anchor=H798956916#H798956916\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\", section on 'Chemotherapy versus targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SYMPTOM PALLIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short courses of radiation therapy (RT) are useful for patients who require palliation of symptoms (eg, dyspnea due to airway obstruction, dysphagia, or hemoptysis), either as part of their initial management or after other treatment has failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple randomized trials have compared lower dose schedules using fewer fractions with more protracted, higher dose schedules. A meta-analysis analyzed results from 13 trials that included 3473 patients who received palliative thoracic radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/30\">",
"     30",
"    </a>",
"    ]. The doses and schedules varied widely in different trials. Longer courses using higher doses were associated with longer survival, but also increased toxicity, primarily manifested as dysphagia.",
"   </p>",
"   <p>",
"    The optimal dose and schedule for symptom palliation is unclear. Longer courses (30 Gy in 10 fractions) represent a reasonable approach for patients with a relatively favorable prognosis for short-term survival. Shorter courses may be more appropriate for those with a poorer prognosis or limited access to an RT facility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/36/40520/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, such symptoms may be due predominantly to endobronchial recurrence. In carefully selected patients, endobronchial brachytherapy or other interventional techniques may be useful in providing symptom palliation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=see_link&amp;anchor=H7#H7\">",
"     \"Endobronchial brachytherapy\", section on 'Palliation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=see_link\">",
"     \"Airway stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=see_link\">",
"     \"Bronchoscopic laser resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=see_link\">",
"     \"Endobronchial electrocautery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38292?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Indications, contraindications, and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RT is also useful in the management of metastatic disease outside the chest. As examples, RT is the primary approach to the management of painful bone metastases and in the treatment of brain metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36486?source=see_link\">",
"     \"Treatment of brain metastases in poor prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/3/1076?source=see_link\">",
"       \"Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/22/41314?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key factors influencing the choice of second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) include the prior treatment received, the presence or absence of specific molecular abnormalities, and patient age and overall condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial treatment generally consists of combination chemotherapy for patients with advanced NSCLC whose tumor does not contain a driver mutation or in whom the results of molecular testing are not known. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link\">",
"       \"Overview of the treatment of advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When patients initially treated with chemotherapy progress and their tumor does not have a driver mutation, single agent chemotherapy is an appropriate treatment option. (See",
"      <a class=\"local\" href=\"#H200193586\">",
"       'Chemotherapy versus EGFR inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who will receive chemotherapy, we recommend single agent chemotherapy rather than combination chemotherapy, since this approach has produced equivalent survival with decreased toxicity (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      both represent appropriate treatment options in this setting; pemetrexed should be limited to patients with nonsquamous histology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chemotherapy agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with advanced NSCLC whose tumors contain either an activating mutation of the epidermal growth factor receptor (EGFR) or the anaplastic lymphoma kinase (ALK) fusion gene generally are initially managed with a molecularly targeted agent. When these patients progress, their subsequent management usually is with combination chemotherapy that is patterned after those who are chemotherapy na&iuml;ve. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When severe symptoms of metastatic or recurrent disease are limited to a single anatomic area, palliative radiation therapy (RT) is often useful for symptom management. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Symptom palliation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link\">",
"       \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/1\">",
"      Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/2\">",
"      Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004; 43:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/3\">",
"      Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/4\">",
"      Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004; 91:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/5\">",
"      Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005; 16:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/6\">",
"      Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005; 23:8389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/7\">",
"      Camps C, Massuti B, Jim&eacute;nez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006; 17:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/8\">",
"      Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/9\">",
"      Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 2005; 41:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/10\">",
"      Tsalic M, Gilboa M, Visel B, et al. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol 2006; 23:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/11\">",
"      Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy 2006; 26:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/12\">",
"      Leyssens B, Wildiers H, Lobelle JP, et al. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Ann Oncol 2010; 21:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/13\">",
"      Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/14\">",
"      Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007; 2:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/15\">",
"      Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/16\">",
"      Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:4405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/17\">",
"      Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/18\">",
"      Nagano T, Kim YH, Goto K, et al. Re-challenge chemotherapy for relapsed non-small-cell lung cancer. Lung Cancer 2010; 69:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/19\">",
"      Socinski MA, Stinchcombe TE, Hayes DN, Morris DE. The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy. Semin Oncol 2006; 33:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/20\">",
"      Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/21\">",
"      Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/22\">",
"      Kim ES,Neubauer MA, Cohn A. SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy (abstract #7502). J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/23\">",
"      Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011; 377:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/24\">",
"      Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and Docetaxel Versus Docetaxel Alone After. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/25\">",
"      Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; 13:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/26\">",
"      Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/27\">",
"      Grassino MC. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR (abstract #LBA7501). J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/28\">",
"      Wagner H Jr. Just enough palliation: radiation dose and outcome in patients with non-small-cell lung cancer. J Clin Oncol 2008; 26:3920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/29\">",
"      Jeremi B, Videtic GM. Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys 2011; 80:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/36/40520/abstract/30\">",
"      Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008; 26:4001.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4620 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40520=[""].join("\n");
var outline_f39_36_40520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEMOTHERAPY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1505317\">",
"      Elderly and poor performance status patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Retreatment after initial response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Relapse after adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H872312\">",
"      TARGETED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1137259613\">",
"      EGFR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1505032\">",
"      Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VEGF pathway inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H200200473\">",
"      Crizotinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H200193586\">",
"      CHEMOTHERAPY VERSUS EGFR INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1505604\">",
"      EGFR MUTATED TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272525172\">",
"      ALK FUSION ONCOGENE TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SYMPTOM PALLIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=related_link\">",
"      Adjuvant systemic therapy in resectable non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38292?source=related_link\">",
"      Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=related_link\">",
"      Endobronchial brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=related_link\">",
"      Endobronchial electrocautery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/22/41314?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=related_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36486?source=related_link\">",
"      Treatment of brain metastases in poor prognosis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_36_40521="Ethinyl estradiol and norgestimate: Drug information";
var content_f39_36_40521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and norgestimate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/45/16086?source=see_link\">",
"    see \"Ethinyl estradiol and norgestimate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Estarylla&trade;;",
"     </li>",
"     <li>",
"      MonoNessa&reg;;",
"     </li>",
"     <li>",
"      Ortho Tri-Cyclen&reg;;",
"     </li>",
"     <li>",
"      Ortho Tri-Cyclen&reg; Lo;",
"     </li>",
"     <li>",
"      Ortho-Cyclen&reg;;",
"     </li>",
"     <li>",
"      Previfem&reg;;",
"     </li>",
"     <li>",
"      Sprintec&reg;;",
"     </li>",
"     <li>",
"      Tri-Estarylla&trade;;",
"     </li>",
"     <li>",
"      Tri-Previfem&reg;;",
"     </li>",
"     <li>",
"      Tri-Sprintec&reg;;",
"     </li>",
"     <li>",
"      TriNessa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclen&reg;;",
"     </li>",
"     <li>",
"      Tri-Cyclen&reg; ;",
"     </li>",
"     <li>",
"      Tri-Cyclen&reg; Lo",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acne (Ortho Tri-Cyclen&reg;): Oral: Refer to dosing for contraception",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Contraception: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day.",
"     <b>",
"      With a Sunday start, an additional method of contraception should be used until after the first 7 days of consecutive administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 21-tablet package: Dosage is 1 tablet daily for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 28-tablet package: Dosage is 1 tablet daily without interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Dose starts on first day of menstrual cycle taking 1 tablet daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 21-tablet package: Dosage is 1 tablet daily for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 28-tablet package: Dosage is 1 tablet daily without interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If all doses have been taken on schedule and one menstrual period is missed, continue dosing cycle. If two consecutive menstrual periods are missed, pregnancy test is required before new dosing cycle is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      monophasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in the first 2 weeks: Take 2 tablets as soon as remembered or 2 tablets next 2 days.",
"     <b>",
"      An additional method of contraception should be used for 7 days after missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 or three consecutive doses missed at any time:",
"     <b>",
"      An additional method of contraception must be used for 7 days after a missed dose:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Continue dose of 1 tablet daily until Sunday, then discard the rest of the pack, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Current pack should be discarded, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      biphasic/triphasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered or take 2 tablets next day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 1 or week 2 of the pack: Take 2 tablets as soon as remembered and 2 tablets the next day. Resume taking 1 tablet daily until the pack is empty.",
"     <b>",
"      An additional method of contraception must be used for 7 days after a missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 of the pack.",
"     <b>",
"      An additional method of contraception must be used for 7 days after a missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Take 1 tablet every day until Sunday. Discard the remaining pack and start a new pack of pills on the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Discard the remaining pack and start a new pack the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Three or more consecutive doses missed.",
"     <b>",
"      An additional method of contraception must be used for 7 days after a missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Take 1 tablet every day until Sunday; on Sunday, discard the pack and start a new pack.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Discard the remaining pack and begin new pack of tablets starting on the same day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Oral: Children &ge;15 years; refer to adult dosing for contraception",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Contraception:",
"     </b>",
"     Oral: Refer to adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution and monitor blood pressure closely. Consider other forms of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F168545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [monophasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estarylla&trade;: Ethinyl estradiol 0.035 mg and norgestimate 0.25 mg [21 blue tablets and 7 green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MonoNessa&reg;, Ortho-Cyclen&reg;: Ethinyl estradiol 0.035 mg and norgestimate 0.25 mg [21 blue tablets and 7 dark green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Previfem&reg;: Ethinyl estradiol 0.035 mg and norgestimate 0.25 mg [21 blue tablets and 7 light green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sprintec&reg;: Ethinyl estradiol 0.035 mg and norgestimate 0.25 mg [21 blue tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [triphasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ortho Tri-Cyclen&reg;, TriNessa&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norgestimate 0.18 mg [7 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norgestimate 0.215 mg [7 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norgestimate 0.25 mg [7 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 dark green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tri-Estarylla&trade;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norgestimate 0.18 mg [7 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norgestimate 0.215 mg [7 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norgestimate 0.25 mg [7 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tri-Previfem&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norgestimate 0.18 mg [7 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norgestimate 0.215 mg [7 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norgestimate 0.25 mg [7 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 light green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tri-Sprintec&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norgestimate 0.18 mg [7 gray tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norgestimate 0.215 mg [7 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norgestimate 0.25 mg [7 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 white inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ortho Tri-Cyclen&reg; Lo:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.025 mg and norgestimate 0.18 mg [7 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.025 mg and norgestimate 0.215 mg [7 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.025 mg and norgestimate 0.25 mg [7 dark blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 dark green inactive tablets (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy; treatment of acne",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F168557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ortho-Cyclen&reg; may be confused with Ortho-Cept&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ortho Tri-Cyclen&reg; may be confused with Ortho Tri-Cyclen&reg; Lo",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vivelle: Brand name for ethinyl estradiol/norgestimate [Austria], but also a brand name for estradiol [U.S. (discontinued), Belgium]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following reactions have been associated with oral contraceptive use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Increased risk or evidence of association with use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, hypertension, mesenteric thrombosis, MI, venous thrombosis (with or without embolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gallbladder disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic adenomas, liver tumors (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions considered drug related:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, varicose vein aggravation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, migraine, mood changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Chloasma, melasma, rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast changes (enlargement, pain, secretion, tenderness), fluid retention, infertility (temporary), lactation decreased (with use immediately postpartum), menstrual flow changes, spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal cramps, abdominal pain, appetite changes, nausea, weight changes, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cervical ectropion, cervical secretion, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Folate decreased, porphyria exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature changes (steepening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions (including angioedema, circulatory collapse, respiratory collapse, urticaria), SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions in which association is not confirmed or denied:",
"     </i>",
"     Acne, Budd-Chiari syndrome, cataracts, colitis, cystitis-like syndrome, dizziness, dysmenorrhea, erythema multiforme, erythema nodosum, headache, hemolytic uremic syndrome, hemorrhagic eruption, hirsutism, libido changes, nervousness, optic neuritis (with or without partial or complete loss of vision), pancreatitis, premenstrual syndrome, renal function impaired, scalp hair loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethinyl estradiol, norgestimate, or any component of the formulation; breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, undiagnosed abnormal uterine bleeding, cholestatic jaundice of pregnancy, jaundice with prior combination hormonal contraceptive use",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), headaches with focal neurological symptoms, hypertension (uncontrolled), valvular heart disease with complications, major surgery with prolonged immobilization",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: May increase the risk of thromboembolism; discontinue use of combination hormonal contraceptives if an arterial or venous thrombotic event occurs. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Presentation of irregular, unresolving vaginal bleeding warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Women with renal disease should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Should not be used in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acne use: For use only in females &ge;15 years, who also desire combination hormonal contraceptive therapy, are unresponsive to topical treatments, and have no contraindications to combination hormonal contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used. New patients should be started on products containing &le;0.035 mg of estrogen per tablet.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F168554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease serum concentrations of the active metabolite(s) of Norgestimate. Management: Use a reliable barrier contraceptive if efavirenz is used in combination with norgestimate.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; a nonhormonal form of contraception is recommended (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F168523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Estarylla Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-35 mg-mcg (28): $32.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mono-Linyah Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-35 mg-mcg (28): $32.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (MonoNessa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-35 mg-mcg (28): $34.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Norgestim-Eth Estrad Triphasic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.18/0.215/0.25 mg-35 mcg (28): $39.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Norgestimate-Eth Estradiol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-35 mg-mcg (28): $36.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ortho Tri-Cyclen Lo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.18/0.215/0.25 mg-25 mcg (28): $126.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sprintec 28 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-35 mg-mcg (28): $32.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tri-Estarylla Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.18/0.215/0.25 mg-35 mcg (28): $39.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tri-Linyah Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.18/0.215/0.25 mg-35 mcg (28): $39.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tri-Previfem Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.18/0.215/0.25 mg-35 mcg (28): $39.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tri-Sprintec Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.18/0.215/0.25 mg-35 mcg (28): $39.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (TriNessa (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.18/0.215/0.25 mg-35 mcg (28): $39.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cilest (AR, BE, BG, CH, CO, CR, CZ, DE, DK, DO, EE, FI, FR, GB, GT, HN, IE, IT, MX, NI, NL, PA, PE, PL, PY, RU, SE, SK, SV, TH, UY);",
"     </li>",
"     <li>",
"      Cileste (AT);",
"     </li>",
"     <li>",
"      Edelsin (ES);",
"     </li>",
"     <li>",
"      Ortho Cyclen (IL);",
"     </li>",
"     <li>",
"      Ortrel (VE);",
"     </li>",
"     <li>",
"      Triafemi (FR);",
"     </li>",
"     <li>",
"      Tricilest (FR, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination hormonal contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Ethinyl estradiol (EE) and norgestimate (NGM): Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EE: &gt;97% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norelgestromin (NGMN): &gt;97% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norgestrel (NG): &gt;97% to sex hormone-binding globulin (SHBG); SHBG capacity is affected by plasma ethinyl estradiol levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EE: Hepatic; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NGM: Hepatic; forms NGMN (major active metabolite) which is further metabolized to NG (active) and other metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EE: 10-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NGMN: 18-25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NG: 38-45 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: EE and NGM: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EE: Urine and feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NGM: Urine (~47%) and feces (~37%) as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/15105794/pubmed\" id=\"15105794\" target=\"_blank\">",
"        15105794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection,&rdquo; August 13, 2001. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orme ML, Back DJ, and Breckenridge AM, &ldquo;Clinical Pharmacokinetics of Oral Contraceptive Steroids,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(2):95-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/6342899/pubmed\" id=\"6342899\" target=\"_blank\">",
"        6342899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shenfield GM and Griffin JM, &ldquo;Clinical Pharmacokinetics of Contraceptive Steroids. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 20(1):15-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/2029800/pubmed\" id=\"2029800\" target=\"_blank\">",
"        2029800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/36/40521/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8742 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40521=[""].join("\n");
var outline_f39_36_40521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708766\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168539\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168540\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168560\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168543\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168553\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168544\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168545\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168516\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168501\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168518\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168517\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168557\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168567\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168558\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168521\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168505\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168554\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168510\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168534\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168512\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168524\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168548\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168525\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168526\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168523\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168514\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168527\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168504\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168520\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8742|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/45/16086?source=related_link\">",
"      Ethinyl estradiol and norgestimate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_36_40522="Cocci lung stain A";
var content_f39_36_40522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75250%7EID%2F55301%7EID%2F68068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75250%7EID%2F55301%7EID%2F68068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coccidioides spp in lung tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spherules of Coccidioides spp in a transbronchial biopsy specimen stained with hematoxylin and eosin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Houck, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coccidioides spp in lung tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Methenamine silver stain of a pleural biopsy specimen, showing small spherules (white arrow), clumps of endospores (blue arrow), and hyphal forms (black arrows; original magnification, x400).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nicolasora, N, Cinti, SK, Riddell Iv, J, Kauffman, CA. Photo quiz. A 53-year-old man with a large air bubble in his chest. Clin Infect Dis 2008; 47:823. Copyright &copy; 2008 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coccidioides spp in lung tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spherules of Coccidioides spp in a transbronchial biopsy specimen stained with periodic acid-Schiff (PAS).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Houck, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40522=[""].join("\n");
var outline_f39_36_40522=null;
var title_f39_36_40523="Morphology prost CA needle bx";
var content_f39_36_40523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Morphologic features associated with malignancy on needle biopsy of the prostate",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Morphologic feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Malignant lesions, percent (n = 100)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Benign lesions, percent (n = 150)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prominent nucleoli",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marginated nucleoli",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple nucleoli",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blue-tinged mucinous secretions",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraluminal crystalloids",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraluminal amorphous eosinophilic material",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collagenous micronodules",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glomerulations",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perineural invasion",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retraction clefting",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invasion of fat",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Varma, M, et al. Arch Pathol Lab Med 2002; 126:554.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40523=[""].join("\n");
var outline_f39_36_40523=null;
var title_f39_36_40524="Antidotes pediatric poisoning A";
var content_f39_36_40524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended antidotes in pediatric poisonings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antidote",
"       </td>",
"       <td class=\"subtitle1\">",
"        Poisoning indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N-acetylcysteine",
"       </td>",
"       <td>",
"        Acetaminophen",
"       </td>",
"       <td>",
"        <p>",
"         Oral Loading dose: 140 mg/kg orally; oral maintenance doses: 70 mg/kg every four hours for 17 doses",
"        </p>",
"        <p>",
"         Intravenous (IV)&nbsp;administration: 150mg/kg over 1 hour (loading dose); 50 mg/kg IV over 4 hours; 100 mg/kg IV over 16 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Atropine",
"       </td>",
"       <td>",
"        Carbamate insecticide",
"       </td>",
"       <td rowspan=\"2\">",
"        0.02 mg/kg IV bolus (0.1 mg minimum dose; maximum single dose 0.5 mg for children and 1.0 mg for adolescents) repeat doses titrated to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organophosphate insecticide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crotalid antivenin",
"       </td>",
"       <td>",
"        Crotalid snakes",
"       </td>",
"       <td>",
"        4 to 6 vials (more if severe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Calcium gluconate and calcium chloride (10 percent)",
"       </td>",
"       <td>",
"        Calcium channel blocker",
"       </td>",
"       <td rowspan=\"2\">",
"        Gluconate: 100 to 200 mg/kg IV Chloride: 20 to 30 mg/kg IV repeat doses and IV infusions are common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrogen fluoride (HF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanide antidote kit (may contain sodium nitrite 3 percent ,sodium thiosulfate, and/or hydroxocobalamin)",
"       </td>",
"       <td>",
"        Cyanide",
"       </td>",
"       <td>",
"        <p>",
"         Sodium thiosulfate: 400 mg/kg IV (maximum 12.5 grams)",
"        </p>",
"        <p>",
"         Hydroxocobalamin: 70 mg/kg IV (maximum 5 grams)",
"        </p>",
"        <p>",
"         Sodium nitrite: 6 mg/kg by slow IV infusion (maximum 300 mg, only give if",
"         <strong>",
"          not",
"         </strong>",
"         contraindicated and hydroxocobolamin is",
"         <strong>",
"          not",
"         </strong>",
"         available), refer to UpToDate topics on cyanide poisoning",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deferoxamine",
"       </td>",
"       <td>",
"        Iron",
"       </td>",
"       <td>",
"        5 to 15 mg/kg per hour IV infusion, titrated to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Digoxin immune Fab",
"       </td>",
"       <td>",
"        Digoxin",
"       </td>",
"       <td rowspan=\"3\">",
"        Empiric dosing: 10 to 20 vials IV bolus fo life-threatening toxicity; see package insert for other dosing regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digitoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural product (eg, plants, toads)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Dimercaprol (BAL, British antilewisite)",
"       </td>",
"       <td>",
"        Acute arsenic",
"       </td>",
"       <td rowspan=\"3\">",
"        2.5 to 4 mg/kg IM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inorganic mercury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead (with encephalopathy)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dart, RC, Goldfrank, LR, Chyka, PA, Lotzer, D. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36:126 and Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1999; 33:735.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40524=[""].join("\n");
var outline_f39_36_40524=null;
var title_f39_36_40525="Inhalation anthrax Rx";
var content_f39_36_40525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of inhalation anthrax associated with bioterrorism*",
"    <sup>",
"     &bull;&Delta;&loz;",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Adults",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Ciprofloxacin 400 mg IV every 12 hrs (preferred agent)*",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Doxycycline 100 mg IV every 12 hrs (only in patients with a major contraindication to ciprofloxacin)",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         One or two additional antimicrobials",
"         <sup>",
"          &sect;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         IV treatment initially",
"         <sup>",
"          &yen;",
"         </sup>",
"         . Switch to oral antimicrobial therapy when clinically appropriate:",
"        </p>",
"        <p>",
"         Ciprofloxacin 500 mg orally twice daily",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Doxycycline 100 mg orally twice daily",
"        </p>",
"        <p>",
"         Continue for 60 days (IV and PO combined)",
"         <sup>",
"          ",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Children",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Ciprofloxacin 10 mg/kg IV every 12 hrs [not to exceed 400 mg/dose] (preferred agent)",
"         <sup>",
"          ",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Doxycycline (only in patients with a major contraindication to ciprofloxacin):",
"        </p>",
"        <p>",
"         &gt;8 yrs old and &gt;45 kg: 100 mg IV every 12 hrs",
"        </p>",
"        <p>",
"         &gt;8 yrs old and &le;45 kg: 2.2 mg/kg IV every 12 hrs",
"        </p>",
"        <p>",
"         &le;8 yrs old: 2.2 mg/kg IV every 12 hrs",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         One or two additional antimicrobials",
"         <sup>",
"          &sect;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         IV treatment initially",
"         <sup>",
"          &yen;",
"         </sup>",
"         . Switch to oral antimicrobial therapy when clinically appropriate:",
"        </p>",
"        <p>",
"         Ciprofloxacin 15 mg/kg orally twice daily*",
"         <sup>",
"          &yen;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Doxycycline:",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         &gt;8 yrs old and &gt;45 kg: 100 mg orally twice daily",
"        </p>",
"        <p>",
"         &gt;8 yrs old and &le;45 kg: 2.2 mg/kg orally twice daily",
"        </p>",
"        <p>",
"         &le;8 yrs old: 2.2 mg/kg orally twice daily",
"        </p>",
"        <p>",
"         Continue for 60 days (IV and PO combined)",
"         <sup>",
"          ",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Pregnant women",
"        </strong>",
"        **",
"       </td>",
"       <td>",
"        Same for nonpregnant adults (the high death rate from the infection outweighs the risk posed by the antimicrobial agent); ciprofloxacin strongly preferred over doxycycline",
"       </td>",
"       <td>",
"        Same for nonpregnant adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Immunocompromised persons",
"        </strong>",
"       </td>",
"       <td>",
"        Same for immunocompetent persons and children",
"       </td>",
"       <td>",
"        Same for immunocompetent persons and children",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Important note: For gastrointestinal and oropharyngeal anthrax, use regimens recommended for inhalational anthrax.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Ciprofloxacin should be considered an essential part of first-line therapy for inhalational anthrax.",
"     <br/>",
"     &Delta; Glucocorticoids may be considered as an adjunct therapy for patients with severe edema or meningitis based on experience with bacterial meningitis of other etiologies.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     In cases with proven meningeal involvement, intravenous therapy with ciprofloxacin plus TWO agents with good CNS penetration (meropenem or imipenem, rifampin, vancomycin, penicillin or ampicillin) and in vitro activity against B. anthracis are recommended.",
"     <br/>",
"     &sect; Additional intravenous antimicrobials with in vitro activity include rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, imipenem, meropenem, clindamycin. At least one of the agents should have good CNS penetration and in vitro activity against B. anthracis (meropenem, imipenem, rifampin, vancomycin, penicillin or ampicillin) due to the potential for clinical or subclinical meningeal involvement. Clindamycin is often suggested as a third agent due to its potential inhibition of toxin production.",
"     <br/>",
"     &yen; Initial therapy may be altered based on clinical response; one or two antimicrobial agents (eg, ciprofloxacin or doxycycline) may be adequate as the patient improves.",
"     <br/>",
"     &Dagger; Because of the potential persistence of spores after an aerosol exposure, antimicrobial therapy should be continued for 60 days.",
"     <br/>",
"     &dagger; If intravenous ciprofloxacin is not available, oral ciprofloxacin may be acceptable because it is rapidly and well absorbed from the gastrointestinal tract with no substantial loss by first-pass metabolism. Maximum serum concentrations are attained 1-2 hours after oral dosing but may not be achieved if vomiting or ileus are present.",
"     <br/>",
"     ** Although doxycycline is not usually recommended during pregnancy, its use may be indicated for life-threatening illness. Adverse effects on developing teeth and bones are dose-related; therefore, doxycycline might be used for a short time (7-14 days) before 6 months of gestation.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:909 and",
"     <br/>",
"     Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:1014 and",
"     <br/>",
"     Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001; 50:960 and",
"     <br/>",
"     Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax [conference summary]. Emerg Infect Dis [serial on the Internet] 2008; 14. file://www.cdc.gov/EID/content/14/4/07-0969.htm (Accessed February 11, 2008).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40525=[""].join("\n");
var outline_f39_36_40525=null;
var title_f39_36_40526="Severe varicose veins";
var content_f39_36_40526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe varicose veins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prominently dilated and tortuous varicose veins associated with moderate hyperpigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40526=[""].join("\n");
var outline_f39_36_40526=null;
var title_f39_36_40527="Knee OA AP x ray";
var content_f39_36_40527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteoarthritis of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior plain radiograph of the knee shows osteophyte formation (arrow), joint space narrowing, and subchondral sclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD, and Celia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_36_40527=[""].join("\n");
var outline_f39_36_40527=null;
